Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Martin Lagging, Rune Wejstål, Ann-Sofi Duberg, Soo Aleman, Ola Weiland & Johan Westin. (2018) Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infectious Diseases 50:8, pages 569-583.
Read now
Read now
Jan Sperl, Sona Frankova, Miluse Kreidlova, Dusan Merta, Monika Tothova & Julius Spicak. (2017) Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Therapeutics and Clinical Risk Management 13, pages 733-738.
Read now
Read now
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman, Ola Weiland, Maria Castedal & Johan Westin. (2017) Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infectious Diseases 49:8, pages 561-575.
Read now
Read now
Regina Juanbeltz, Silvia Goñi Esarte, Juan Isidro Úriz-Otano, Ana Martínez Echeverría, Inmaculada Elizalde, José Manuel Zozaya, Jesús Castilla & Ramón San Miguel. (2017) Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine 129:4, pages 476-483.
Read now
Read now
Mohamed El Kassas, Tamer Elbaz, Enas Hafez & Gamal Esmat. (2016) Safety of direct antiviral agents in the management of hepatitis C. Expert Opinion on Drug Safety 15:12, pages 1643-1652.
Read now
Read now
Vicente Gimeno-Ballester, Miguel Ángel Simón, Cristina Trigo, Javier Mar & Ramón San Miguel. (2016) Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Review of Gastroenterology & Hepatology 10:11, pages 1289-1303.
Read now
Read now
Onyema Ogbuagu, Gerald Friedland & R. Douglas Bruce. (2016) Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 721-731.
Read now
Read now
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman, Ola Weiland, Maria Castedal & Filip Josephson. (2016) Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infectious Diseases 48:4, pages 251-261.
Read now
Read now
Articles from other publishers (53)
Tari George Michael, Christina A. Anwar, Ossama A. Ahmed, Iman Sarhan, Yehia Elshazly, Mohammed K. Shaker, Mohammed Eltabbakh, Walaa Hashem, Safaa R. Tawfic, Shimaa Y. Kamel, Doaa M. Kandil, Gina G. Naguib, Abdelrahman Khedr, Eman A. Ghanem, Hany Dabbous, Wahid Doss & Manal H. El-Sayed. (2022) Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study. The Egyptian Journal of Internal Medicine 34:1.
Crossref
Crossref
Meghan E Sise, Thomas McQuaid & Paul Martin. (2022) Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrology Dialysis Transplantation 37:12, pages 2327-2334.
Crossref
Crossref
Ming-Lung Yu, Chung-Feng Huang, Yu-Ju Wei, Wen-Yi Lin, Yi-Hung Lin, Po-Yao Hsu, Cheng-Ting Hsu, Ta Wei Liu, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Tzu-Sui Hung, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Ming-Yen Hsieh, Szu-Chia Chen, Jee-Fu Huang, Jer-Ming Chang, Yi-Wen Chiu, Chia-Yen Dai, Shang-Jyh Hwang & Wan-Long Chuang. (2021) Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut 70:12, pages 2349-2358.
Crossref
Crossref
Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit & Ezequiel Ridruejo. (2021) Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 41:5, pages 578-589.
Crossref
Crossref
Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit & Ezequiel Ridruejo. (2021) Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología 41:5, pages 578-589.
Crossref
Crossref
Sara Majd Jabbari, Khadije Maajani, Shahin Merat, Hossein Poustchi & Sadaf G. Sepanlou. (2021) An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLOS ONE 16:2, pages e0246594.
Crossref
Crossref
Hongling Yang, Xiao Hu, Lei Pu, Song Ren & Yunlin Feng. (2020) Efficacy and safety of direct‐acting antiviral‐based treatment in hepatitis C virus infected patients with chronic renal function impairment: An updated systemic review and meta‐analysis. Nephrology 25:11, pages 829-838.
Crossref
Crossref
Eric Lawitz, Charles S Landis, Steven L Flamm, Maurizio Bonacini, Grisell Ortiz-Lasanta, Jonathan Huang, Jie Zhang, Brian J Kirby, Shampa De-Oertel, Robert H Hyland, Anu O Osinusi, Diana M Brainard, Richard Robson, Benedict J Maliakkal, Stuart C Gordon & Edward J Gane. (2020) Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. The Lancet Gastroenterology & Hepatology 5:10, pages 918-926.
Crossref
Crossref
Rasha Eletreby, Magdy El‐Serafy, Mahmoud Anees, Gamal Kasem, Marwa Salama, Reham Elkhouly, Mostafa Hamdy, Hisham Abdel Haleem, Ehab Kamal, Wael Abdel‐Razek, Rabab Salama, Mohamed Elshenawy, Ayman Shafeek, Mohamed Hassany, Manal H. El‐Sayed, Yehia El‐Shazly & Gamal Esmat. (2020) Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver International 40:4, pages 797-805.
Crossref
Crossref
Fernanda Bellini Lunardi MICHELS, Ana Cristina de Castro AMARAL, Roberto José de CARVALHO-FILHO, Gustavo de Almeida VIEIRA, Ana Lucia da Silva SOUZA & Maria Lucia Gomes FERRAZ. (2020) HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arquivos de Gastroenterologia 57:1, pages 45-49.
Crossref
Crossref
Matt Driedger, Chrissi Galanakis & Curtis Cooper. (2020) Direct acting antiviral HCV treatment does not influence renal function. Medicine 99:22, pages e20436.
Crossref
Crossref
Vinicius Lins Ferreira, Leticia Paula Leonart, Ana Maria Della Rocca & Roberto Pontarolo. (2019) Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case Reports. Current Drug Therapy 14:3, pages 210-219.
Crossref
Crossref
Sergio M. Borgia, Janet Dearden, Eric M. Yoshida, Stephen D. Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E. Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J. Kirby, Amy Meng, Svetlana Markova, Hadas Dvory-Sobol, Anu O. Osinusi, Rafael Bruck, Javier Ampuero, Stephen D. Ryder, Kosh Agarwal, Raymond Fox, David Shaw, Shariq Haider, Bernard Willems, Yoav Lurie, Jose Luis Calleja & Edward J. Gane. (2019) Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Journal of Hepatology 71:4, pages 660-665.
Crossref
Crossref
Eleni Koukoulioti & Thomas Berg. 2019. Evidence-based Gastroenterology and Hepatology 4e. Evidence-based Gastroenterology and Hepatology 4e
470
489
.
Elizabeth Cohen & AnnMarie Liapakis. (2019) Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. Seminars in Dialysis 32:2, pages 141-151.
Crossref
Crossref
Annette Bruchfeld & Karin Lindahl. (2019) Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. Seminars in Dialysis 32:2, pages 135-140.
Crossref
Crossref
Diğdem Özer Etik, Nuretdin Suna, Serkan Öcal, Haldun Selçuk, Ülkü Dağlı, Turan Çolak, Fatih Hilmioğlu, Ahmet Sedat Boyacıoğlu & Mehmet Haberal. (2019) Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients. Experimental and Clinical Transplantation 17:1, pages 52-58.
Crossref
Crossref
Eva M. Teegen, Michael Dürr, Max M. Maurer, Franziska Eurich, Antonia Vollbort, Brigitta Globke, Marcus Bahra, Hendrik Blaeker, Johann Pratschke & Dennis Eurich. (2019) Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence. Transplant Infectious Disease 21:1, pages e13020.
Crossref
Crossref
Soon Young Ko & Won Hyeok Choe. (2018) Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clinical and Molecular Hepatology 24:4, pages 351-357.
Crossref
Crossref
Manoj Kumar, Suman L. Nayak, Ekta Gupta, Ashish Kataria & Shiv K. Sarin. (2018) Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver International 38:12, pages 2137-2148.
Crossref
Crossref
Akash Singh, Sunita Kumari, Pramod Kumar, Arka De & Virendra Singh. (2018) Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. Journal of Viral Hepatitis 25:12, pages 1501-1506.
Crossref
Crossref
Sandra E. Reznik, Amit K. Tiwari & Charles R. AshbyJr.Jr.. (2018) Sofosbuvir: A Potential Treatment for Ebola. Frontiers in Pharmacology 9.
Crossref
Crossref
T. Medeiros, N. F. Rosário, G. N. Saraiva, T. G. Andrade, A. A. Silva & J. R. Almeida. (2018) Renal safety after one year of sofosbuvir‐based therapy for chronic hepatitis C: A Brazilian “real‐life” study. Journal of Clinical Pharmacy and Therapeutics 43:5, pages 707-713.
Crossref
Crossref
Maurizio Salvadori & Aris Tsalouchos. (2018) Hepatitis C and renal transplantation in era of new antiviral agents. World Journal of Transplantation 8:4, pages 84-96.
Crossref
Crossref
Rebeca García-Agudo, Sami Aoufi-Rabih, Mercedes Salgueira-Lazo, Carmen González-Corvillo & Fabrizio Fabrizi. (2018) ‘Real-life’ experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. The International Journal of Artificial Organs 41:7, pages 363-370.
Crossref
Crossref
Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta & Carlo Torti. (2018) Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. Clinical and Molecular Hepatology 24:2, pages 151-162.
Crossref
Crossref
Geoffrey Dusheiko. 2018. Sherlock's Diseases of the Liver and Biliary System. Sherlock's Diseases of the Liver and Biliary System
436
467
.
Sunil Taneja, Ajay Duseja, Arka De, Manu Mehta, Raja Ramachandran, Vivek Kumar, Harbir Singh Kohli, Krishan Lal Gupta, Radha Krishan Dhiman & Yogesh Chawla. (2018) Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Digestive Diseases and Sciences 63:5, pages 1334-1340.
Crossref
Crossref
Mandarapu Surendra, Sree Bhushan Raju, Nimmagadda Sridhar, Bangillapati Vijay Kiran, Goli Rajesh, Golla Anvesh & Nallagasu Raju. (2017) Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study. Hemodialysis International 22:2, pages 217-221.
Crossref
Crossref
Fabrizio Fabrizi, Francesco Negro, Mark Bondin & Patrice Cacoub. (2018) Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection. Antiviral Therapy 23:1_suppl, pages 57-67.
Crossref
Crossref
Masanori Atsukawa, Akihito Tsubota, Yohei Koushima, Tadashi Ikegami, Kouji Watanabe, Noritomo Shimada, Shinichi Sato, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Taeang Arai, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki & Katsuhiko Iwakiri. (2017) Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatology Research 47:13, pages 1429-1437.
Crossref
Crossref
Fabrizio Fabrizi, Francesca M. Donato & Piergiorgio Messa. (2017) Direct-acting Antivirals for Hepatitis C Virus in Patients on Maintenance Dialysis. The International Journal of Artificial Organs 40:10, pages 531-541.
Crossref
Crossref
Richard J. Johnson & Michiko Shimada. (2017) Contemporary Management of Hepatitis C in Patients with CKD. Clinical Journal of the American Society of Nephrology 12:10, pages 1563-1565.
Crossref
Crossref
Sanjay Kumar Agarwal, Soumita Bagchi & Raj Kumar Yadav. (2017) Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. Kidney International Reports 2:5, pages 831-835.
Crossref
Crossref
Matthias Girndt. (2017) Treating hepatitis C virus in patients with chronic renal failure. The Lancet Gastroenterology & Hepatology 2:8, pages 544-546.
Crossref
Crossref
Tao Li, Yundong Qu, Ying Guo, Yan Wang & Lei Wang. (2017) Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver International 37:7, pages 974-981.
Crossref
Crossref
M. Mendizabal & K. R. Reddy. (2017) Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. Journal of Viral Hepatitis 24:6, pages 442-453.
Crossref
Crossref
Norah A. Terrault, Geoff W. McCaughan, Michael P. Curry, Edward Gane, Stefano Fagiuoli, James Y. Y. Fung, Kosh Agarwal, Les Lilly, Simone I. Strasser, Kimberly A. Brown, Adrian Gadano, Paul Y. Kwo, Patrizia Burra, Didier Samuel, Michael Charlton, Mario G. Pessoa & Marina Berenguer. (2017) International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation 101:5, pages 945-955.
Crossref
Crossref
Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya & Charles S. Landis. (2017) Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatology Communications 1:3, pages 248-255.
Crossref
Crossref
Marcus M. Mücke, Victoria T. Mücke, Christian M. Lange & Stefan Zeuzem. (2017) Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. Liver International 37, pages 19-25.
Crossref
Crossref
. (2017) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology 66:1, pages 153-194.
Crossref
Crossref
Lionel Rostaing, Laurent Alric & Nassim Kamar. (2016) Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transplant International 29:12, pages 1257-1265.
Crossref
Crossref
Autumn Bagwell & Cody A. Chastain. (2016) Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities. Current Treatment Options in Infectious Diseases 8:4, pages 379-399.
Crossref
Crossref
Poonam Mathur, Shyamasundaran Kottilil & Jennifer Husson. (2016) Treatment of hepatitis C in renal impairment and renal transplant. Current Treatment Options in Infectious Diseases 8:4, pages 438-448.
Crossref
Crossref
Justin Taylor, Paula Cox-North & Charles S. Landis. (2016) Management of Post-Liver Transplant Recurrence of Hepatitis C. Drugs 76:18, pages 1711-1717.
Crossref
Crossref
Patrice Cacoub, Anne Claire Desbois, Corinne Isnard-Bagnis, Dario Rocatello & Clodoveo Ferri. (2016) Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. Journal of Hepatology 65:1, pages S82-S94.
Crossref
Crossref
Sandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Albert Friedrich Stättermayer, Rudolf Stauber, Michael Strasser, Heinz Zoller, Bruno Watschinger, Alice Schmidt, Michael Trauner, Harald Hofer & Andreas Maieron. (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International 29:9, pages 999-1007.
Crossref
Crossref
Kalyan Ram Bhamidimarri & Paul Martin. (2016) Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. Journal of Hepatology 65:1, pages 7-10.
Crossref
Crossref
Varun Saxena, Farrukh M. Koraishy, Meghan E. Sise, Joseph K. Lim, Monica Schmidt, Raymond T. Chung, Annmarie Liapakis, David R. Nelson, Michael W. Fried & Norah A. Terrault. (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver International 36:6, pages 807-816.
Crossref
Crossref
Tavankit Singh, John Guirguis, Sumi Anthony, John Rivas, Ibrahim A. Hanouneh & Naim Alkhouri. (2016) Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver International 36:6, pages 802-806.
Crossref
Crossref
Fabrizio Fabrizi, Paul Martin & Piergiorgio Messa. (2016) New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney International 89:5, pages 988-994.
Crossref
Crossref
Tianyan Chen & Norah A. Terrault. (2016) Perspectives on treating hepatitis C infection in the liver transplantation setting. Current Opinion in Organ Transplantation 21:2, pages 111-119.
Crossref
Crossref
. (2016) Peginterferon-alfa/ribavirin/sofosbuvir. Reactions Weekly 1583:1, pages 865-865.
Crossref
Crossref